Reversal of novel oral anticoagulants in patients with major bleeding

Novel oral anticoagulants (NOACs) that directly inhibit thrombin (dabigatran) or factor Xa (rivaroxaban, apixaban, edoxaban) are effective therapies for the prevention and treatment of thromboembolism with reduced bleeding complications compared with warfarin for some indications. However, specific antidotes to reverse the anticoagulant activity of NOACs in… (More)
  • Blog articles referencing this paper

    • Noreversaban?

      R.E.B.E.L. EM - Emergency Medicine Blog · Nov 05, 2015

    • Don't see an article that should be here?

  • Presentations referencing similar topics